Artiva Biotherapeutics (ARTV) closed at $3.83 on November 19, 2026, up 1.6% from the previous close, on volume of 769,406 shares (30-day average 1,103,360).
Data as of November 19, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 18, 2026. See the largest for 5, 30, 60 and 90 days
Globe Newswire (Tue, 17-Nov 6:13 PM ET)
Business Wire (Tue, 17-Nov 3:55 PM ET)
ACCESS Newswire (Fri, 13-Nov 10:30 AM ET)
PRNewswire (Thu, 12-Nov 10:15 AM ET)
Artiva halts AlloNK after durability fell short and two Grade 5 events were disclosed
Market Chameleon (Tue, 27-Oct 4:55 AM ET)
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
Globe Newswire (Tue, 27-Oct 7:30 AM ET)
Globe Newswire (Fri, 2-Oct 9:05 AM ET)
Globe Newswire (Thu, 1-Oct 7:30 AM ET)
Globe Newswire (Wed, 23-Sep 7:30 AM ET)
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Globe Newswire (Thu, 17-Sep 8:00 AM ET)
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Artiva Biotherapeutics trades on the NASDAQ stock market under the symbol ARTV.
As of November 19, 2026, ARTV stock price climbed to $3.83 with 769,406 million shares trading.
ARTV has a beta of 3.95, meaning it tends to be more sensitive to market movements. ARTV has a correlation of 0.18 to the broad based SPY ETF.
ARTV has a market cap of $187.25 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that ARTV belongs to (by Net Assets): VTI, IWM, VXF, VFMO, IWN.
ARTV has underperformed the market in the last year with a price return of -1.5% while the SPY ETF gained +9.6%. ARTV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.2% and -9.2%, respectively, while the SPY returned -6.5% and -6.6%, respectively.
ARTV support price is $3.62 and resistance is $3.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTV shares will trade within this expected range on the day.